272 related articles for article (PubMed ID: 26938745)
1. Genome Wide Mapping of NR4A Binding Reveals Cooperativity with ETS Factors to Promote Epigenetic Activation of Distal Enhancers in Acute Myeloid Leukemia Cells.
Duren RP; Boudreaux SP; Conneely OM
PLoS One; 2016; 11(3):e0150450. PubMed ID: 26938745
[TBL] [Abstract][Full Text] [Related]
2. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
3. Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia.
Boudreaux SP; Duren RP; Call SG; Nguyen L; Freire PR; Narayanan P; Redell MS; Conneely OM
Leukemia; 2019 Jan; 33(1):52-63. PubMed ID: 29884904
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide profiling reveals transcriptional repression of MYC as a core component of NR4A tumor suppression in acute myeloid leukemia.
Boudreaux SP; Ramirez-Herrick AM; Duren RP; Conneely OM
Oncogenesis; 2012 Jul; 1(7):e19. PubMed ID: 23552735
[TBL] [Abstract][Full Text] [Related]
5. Reduced NR4A gene dosage leads to mixed myelodysplastic/myeloproliferative neoplasms in mice.
Ramirez-Herrick AM; Mullican SE; Sheehan AM; Conneely OM
Blood; 2011 Mar; 117(9):2681-90. PubMed ID: 21205929
[TBL] [Abstract][Full Text] [Related]
6. The nuclear orphan receptor NR4A1 and NR4A3 as tumor suppressors in hematologic neoplasms.
Wenzl K; Troppan K; Neumeister P; Deutsch AJ
Curr Drug Targets; 2015; 16(1):38-46. PubMed ID: 25410408
[TBL] [Abstract][Full Text] [Related]
7. NR4A1 and NR4A3 restrict HSC proliferation via reciprocal regulation of C/EBPα and inflammatory signaling.
Freire PR; Conneely OM
Blood; 2018 Mar; 131(10):1081-1093. PubMed ID: 29343483
[TBL] [Abstract][Full Text] [Related]
8. Activity of a heptad of transcription factors is associated with stem cell programs and clinical outcome in acute myeloid leukemia.
Diffner E; Beck D; Gudgin E; Thoms JA; Knezevic K; Pridans C; Foster S; Goode D; Lim WK; Boelen L; Metzeler KH; Micklem G; Bohlander SK; Buske C; Burnett A; Ottersbach K; Vassiliou GS; Olivier J; Wong JW; Göttgens B; Huntly BJ; Pimanda JE
Blood; 2013 Mar; 121(12):2289-300. PubMed ID: 23327922
[TBL] [Abstract][Full Text] [Related]
9. Histone acetylation regulates orphan nuclear receptor NR4A1 expression in hypercholesterolaemia.
Xie X; Song X; Yuan S; Cai H; Chen Y; Chang X; Liang B; Huang D
Clin Sci (Lond); 2015 Dec; 129(12):1151-61. PubMed ID: 26396259
[TBL] [Abstract][Full Text] [Related]
10. The nuclear orphan receptors NR4A as therapeutic target in cancer therapy.
Deutsch AJ; Angerer H; Fuchs TE; Neumeister P
Anticancer Agents Med Chem; 2012 Nov; 12(9):1001-14. PubMed ID: 22583411
[TBL] [Abstract][Full Text] [Related]
11. The nuclear receptors NUR77, NURR1 and NOR1 in obesity and during fat loss.
Veum VL; Dankel SN; Gjerde J; Nielsen HJ; Solsvik MH; Haugen C; Christensen BJ; Hoang T; Fadnes DJ; Busch C; Våge V; Sagen JV; Mellgren G
Int J Obes (Lond); 2012 Sep; 36(9):1195-202. PubMed ID: 22143616
[TBL] [Abstract][Full Text] [Related]
12. The oncofusion protein FUS-ERG targets key hematopoietic regulators and modulates the all-trans retinoic acid signaling pathway in t(16;21) acute myeloid leukemia.
Sotoca AM; Prange KH; Reijnders B; Mandoli A; Nguyen LN; Stunnenberg HG; Martens JH
Oncogene; 2016 Apr; 35(15):1965-76. PubMed ID: 26148230
[TBL] [Abstract][Full Text] [Related]
13. Genome-wide mapping of histone H3K9me2 in acute myeloid leukemia reveals large chromosomal domains associated with massive gene silencing and sites of genome instability.
Salzberg AC; Harris-Becker A; Popova EY; Keasey N; Loughran TP; Claxton DF; Grigoryev SA
PLoS One; 2017; 12(3):e0173723. PubMed ID: 28301528
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of mRNA Expressions of TOX and NR4As in CD8+ T cells in Acute Leukemia.
Mohammadi M; Asgarian-Omran H; Najafi B; Najafi A; Valadan R; Karami H; Naderisoraki M; Alizadeforoutan M; Shekarriz R; Tehrani M
Iran J Immunol; 2023 Dec; 20(4):438-445. PubMed ID: 37961948
[TBL] [Abstract][Full Text] [Related]
15. AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis.
Singh AA; Mandoli A; Prange KH; Laakso M; Martens JH
Oncotarget; 2017 Feb; 8(8):12855-12865. PubMed ID: 28030795
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal COX2-PG secretome engages NR4A-WNT signalling axis in haematopoietic progenitors to suppress anti-leukaemia immunity.
Wu L; Amarachintha S; Xu J; Oley F; Du W
Br J Haematol; 2018 Nov; 183(3):445-456. PubMed ID: 30106181
[TBL] [Abstract][Full Text] [Related]
17. BET Bromodomain Inhibition Suppresses the Function of Hematopoietic Transcription Factors in Acute Myeloid Leukemia.
Roe JS; Mercan F; Rivera K; Pappin DJ; Vakoc CR
Mol Cell; 2015 Jun; 58(6):1028-39. PubMed ID: 25982114
[TBL] [Abstract][Full Text] [Related]
18. NR4A orphan nuclear receptors: transcriptional regulators of gene expression in metabolism and vascular biology.
Zhao Y; Bruemmer D
Arterioscler Thromb Vasc Biol; 2010 Aug; 30(8):1535-41. PubMed ID: 20631354
[TBL] [Abstract][Full Text] [Related]
19. The natural anti-tumor compound Celastrol targets a Myb-C/EBPβ-p300 transcriptional module implicated in myeloid gene expression.
Coulibaly A; Haas A; Steinmann S; Jakobs A; Schmidt TJ; Klempnauer KH
PLoS One; 2018; 13(2):e0190934. PubMed ID: 29394256
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterization of Hoxa9 binding sites in hematopoietic cells.
Huang Y; Sitwala K; Bronstein J; Sanders D; Dandekar M; Collins C; Robertson G; MacDonald J; Cezard T; Bilenky M; Thiessen N; Zhao Y; Zeng T; Hirst M; Hero A; Jones S; Hess JL
Blood; 2012 Jan; 119(2):388-98. PubMed ID: 22072553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
